TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21593282
Drug: MS-sNT administered
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-sNT administered with 240 mL of 4% alcohol
Study: 21593282
Drug: MS-sNT administered
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-sNT administered with 240 mL of 20% alcohol
Study: 21593282
Drug: MS-sNT administered
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-sNT administered with 240 mL of 40% alcohol
Study: 21593282
Drug: MS-sNT administered
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-sNT administered with water
Study: 12613392
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prescribed medication and light physical exercises like walking).
Study: 7651647
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (3.75 or 7.5 mg) in three monthly doses
Study: 7651647
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (GnRH agonist)
Study: 2613931
Drug: Adhesive antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive antibiotic TA (0.1 mg, 4 applications)
Study: 361346
Drug: Nefopam (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (90 mg)
Study: 30255229
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of S-25(OH)D levels (105.3 nmol/L)
Study: 30255229
Drug: Middle quartiles
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle quartiles of S-25(OH)D levels (74.5 nmol/L and 85.7 nmol/L)
Study: 30255229
Drug: Lowest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest quartile of S-25(OH)D levels (59.3 nmol/L)
Study: 17674415
Drug: Methylphenidate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10 mg three times per day, n = 17)
Study: 9017481
Drug: Saline (2-cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (2-cc vials)
Study: 8357508
Drug: Oral‐B 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B 40 toothbrush
Study: 3531313
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg vs Ranitidine
Study: 24107382
Drug: Difficulties in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difficulties in instrumental activities of daily living, balance, outdoor mobility
Study: 20864600
Drug: SNRB+PT (Selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNRB+PT (Selective Nerve Root Block + Physical Therapy)
Study: 18343300
Drug: Pharmaceutical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical treatments (specifics not available)
Study: 27629797
Drug: Psychosocial variables
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial variables (self-efficacy, treatment expectation, social support)
Study: 23341160
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of ß‐lactam antibiotics (meropenem, piperacillin‐tazobactam, cefepime) over 30 minutes
Study: 23341160
Drug: Prolonged infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged infusion of ß‐lactam antibiotics (meropenem, piperacillin‐tazobactam, cefepime) over 3 hours
Study: 23341160
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of ß‐lactam antibiotics
Study: 23341160
Drug: Prolonged infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged infusion of ß‐lactam antibiotics
Study: 23341160
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion group
Study: 23341160
Drug: Prolonged infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged infusion group
Study: 17076053
Drug: High quality
Normalized name: COCONUT OIL 5 g in 30 mL TOPICAL OIL [High Quality Natural Rosemary]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High quality treatment as usual (control group)
Study: 9114913
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing (o.d.) of modified-release carbamazepine (CBZ-MR)
Study: 9114913
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing (b.d.) of modified-release carbamazepine (CBZ-MR)
Study: 3303997
Drug: Cladosporium allergen
Normalized name: Cladosporium herbarum allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladosporium allergen preparation
Study: 31838029
Drug: Oral metolazone
Normalized name: Metolazone
DrugBank: Metolazone (DB00524)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metolazone
Study: 21435540
Drug: Implant-anchored treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-anchored treatment (IA group)
Study: 21435540
Drug: Conventional edgewise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional edgewise treatment (non-IA group)
Study: 24163282
Drug: Pooled Sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pooled Sumatriptan (25 mg and 50 mg)
Study: 22190398
Drug: rPA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rPA vaccine (formalin treated, alum adsorbed, or both)
Study: 22190398
Drug: rPA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rPA vaccine
Study: 22190398
Drug: AVA (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVA (licensed vaccine)
Study: 18534975
Drug: Sildenafil (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (0.7 mg/kg body weight, single oral dose)
Study: 17135987
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluoxetine and cognitive-behavioral therapy (COMB)
Study: 11011281
Drug: 0.1% estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% estradiol gel (Gel A)
Study: 6374193
Drug: Cefaclor (CCL)
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor (CCL) administered 3 times a day at a daily dosage of 750 mg for 3 to 5 days.
Study: 6374193
Drug: Cephalexin (CEX)
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (CEX) administered 4 times a day at a daily dosage of 1,000 mg for 3 to 5 days.
Study: 22301087
Drug: Group cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive‐behavioral therapy (CBT) for depression and substance use
Study: 16108771
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of Peginterferon alpha‐2b + ribavirin (Group A)
Study: 16108771
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of Peginterferon alpha‐2b administered twice weekly + ribavirin (Group B)
Study: 6239753
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg meptazinol 4-times daily for up to 3 weeks
Study: 6239753
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg diflunisal 4-times daily for up to 3 weeks
Study: 31021886
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg intravenous dexamethasone before incision
Study: 31021886
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral pregabalin 1 hour before surgery
Study: 31021886
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.2 mg/kg intravenous dexamethasone and 150 mg oral pregabalin
Study: 27568165
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education program (n=817) consisting of weekly to monthly workshops covering relevant health information
Study: 9274835
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate Mofetil (MMF) in conjunction with ciclosporin and steroids
Study: 9274835
Drug: Ciclosporin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin and steroids
Study: 24886488
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg once daily in addition to routine care
Study: 23570952
Drug: Various antidepressants
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various antidepressants and augmentation strategies including extended-release venlafaxine, mitazapine, paroxetine, risperidone, sodium valproate, buspirone, trazodone, thyroid hormone augmenting to paroxetine
Study: 17121727
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine combined with fentanyl (KF group)
Study: 10223773
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg once a day for 5 days
Study: 6806060
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cimetidine in the evening (group A)
Study: 6806060
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cimetidine both morning and evening (group B)
Study: 30523032
Drug: Roux-en-Y gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roux-en-Y gastric bypass (RYGB) with exendin(9-39) infusion
Study: 21390540
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention (Project EXPLORE), details on dosage and duration not specified.
Study: 7049307
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg on the day of operation and for the following 2 days)
Study: 31487406
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg (T100)
Study: 31487406
Drug: Tildrakizumab 200
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 200 mg (T200)
Study: 31487406
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg (T100) with placebo (PBO)
Study: 31487406
Drug: Tildrakizumab 200
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 200 mg (T200) with placebo (PBO)
Study: 31487406
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) switching to Tildrakizumab 200 mg (ETN/T200)
Study: 24122669
Drug: Artemether-lumefantrine (A-L)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (A-L)
Study: 21615951
Drug: Problem solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem solving therapy, regular written communication, patient support, cultural assessment, improved access to primary care, risk management strategy
Study: 21615951
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (treatment as usual)
Study: 18305265
Drug: Low-dose vasopressin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vasopressin (0.01 to 0.03 U per minute)
Study: 18305265
Drug: Low-dose vasopressin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vasopressin (0.01 to 0.03 U per minute) in less severe septic shock
Study: 18305265
Drug: Low-dose vasopressin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vasopressin (0.01 to 0.03 U per minute) in more severe septic shock
Study: 15945499
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (appropriate medications)
Study: 8578059
Drug: Gabapentin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (900 to 1800 mg/day)
Study: 2054316
Drug: Epirubicin 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 120 mg/m2 i.v. push every 21 days pre-operatively, and four additional courses post-operatively (group I)
Study: 2054316
Drug: Histopathological study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histopathological study of resected specimens after initial chemotherapy
Study: 24892115
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral hygiene procedures (1 hour session)
Study: 19571597
Drug: sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline plus atomoxetine
Study: 17890427
Drug: Rosiglitazone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone therapy for 12 weeks
Study: 15375799
Drug: glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: glibenclamide (5 mg/d)
Study: 15375799
Drug: voglibose (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: voglibose (0.6 mg/d)
Study: 27143662
Drug: Ritonavir-boosted protease
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted protease inhibitor monotherapy (PI-monotherapy)
Study: 27143662
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination ART (OT group)
Study: 18782697
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia alone
Study: 16640102
Drug: Atazanavir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir (300 mg once daily) boosted by Ritonavir (100 mg) for 2 weeks, followed by ATV, RTV, and TDF-DF (300 mg) plus optimized NRTIs regimen.
Study: 10949980
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 1 g cefodizime
Study: 10949980
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 1 g cefodizime
Study: 10949980
Drug: Skin suction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin suction blister fluid (SBF) after cefodizime administration
Study: 7935568
Drug: Fluconazole, 200
Normalized name: Fluconazole, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole, 200 mg once a day
Study: 7935568
Drug: Oral amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amphotericin B, 800 mg three times a day
Study: 3741534
Drug: Metronidazole, 500
Normalized name: MetroNIDAZOLE, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole, 500 mg i.v.
Study: 3741534
Drug: Latamoxef (lamoxactam),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latamoxef (lamoxactam), 2 g i.v.
Study: 17477110
Drug: Drospirenone in
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone in combination with 17β‐estradiol
Study: 15110210
Drug: Sequential acquisition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential acquisition protocol
Study: 11812391
Drug: Fluid ingestion
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid ingestion (H1 and E1) - solution containing 50 g l(‐1) glucose and 1.34 g l(‐1) NaCl in a volume of water corresponding to 100% of body weight loss
Study: 11812391
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (H0, E0) - solution containing the same quantity of glucose diluted in 100 ml of water
Study: 319116
Drug: Indomethacin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (80 mg/day)
Study: 30735919
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus metronomic chemotherapy (capecitabine 500 mg three times per day and cyclophosphamide 50 mg/die)
Study: 30735919
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus metronomic chemotherapy (capecitabine and cyclophosphamide)
Study: 22404081
Drug: Functionally orientated
Normalized name: Papaver orientale seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functionally orientated treatment using resin-bonded bridgework (RBB) to restore to a Shortened Dental Arch (SDA) of 10 occluding contacts
Study: 22001281
Drug: Separate vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate vaccines (DTaP, IPV, PRP∼T) booster
Study: 19858155
Drug: Pramlintide (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (maximum dose: 30 microg per meal)
Study: 16622259
Drug: docetaxel 43
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 43 mg/m2 weekly alone (cohort A)
Study: 16622259
Drug: docetaxel 43
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 43 mg/m2 weekly plus etanercept 25 mg subcutaneously twice weekly (cohort B)
Study: 16622259
Drug: docetaxel 52
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 52 mg/m2 weekly with etanercept
Study: 15642958
Drug: Dihydroartemisinin formulations
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin formulations (Cotecxin, Arenco n.v. Pharmaceutica, Mahidol University)
Study: 15642958
Drug: Dihydroartemisinin formulations
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin formulations
Study: 9849452
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care plus chemotherapy (carboplatin 300 mg/m2 on day 1 and etoposide 120 mg/m2 orally on days 1-5 every 4 weeks for a maximum of eight courses)
Study: 3047337
Drug: Chemotherapy (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (exact regimen not specified)
Study: 7812703
Drug: Half doses
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half doses of drugs at the first cycle (suggested intervention)
Study: 31729127
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of the ACE-inhibitor, perindopril, and the thiazide-like diuretic, indapamide
Study: 31729127
Drug: Sulphonylurea gliclazide
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylurea gliclazide plus other glucose-lowering drugs targeting a glycated hemoglobin value of 6.5% or less
Study: 25675123
Drug: Erlotinib (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (once daily)
Study: 25675123
Drug: Chemotherapy (3-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (3-weekly cycles)
Study: 23241734
Drug: Nefopam-Paracetamol combination
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam-Paracetamol combination
Study: 23241734
Drug: Nefopam and
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam and Paracetamol combination
Study: 19040340
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs and new approaches including response prediction based on sequential (18)FDG‐PET scanning following induction chemotherapy
Study: 8057515
Drug: Maximized glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximized glycemic control (subcutaneous insulin given several times a day or continuously)
Study: 8057515
Drug: Standard glycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glycemic control (subcutaneous insulin given once or twice each day)
Study: 8057515
Drug: Maximized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximized treatment
Study: 3140744
Drug: L-arginine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (25 g/day, n = 16)
Study: 3140744
Drug: L-glycine (43
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glycine (43 g/day, n = 14)
Study: 31513665
Drug: Anakinra (IL-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (IL-1 inhibitor)
Study: 31513665
Drug: TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab, golimumab)
Study: 29021371
Drug: Double-fortified salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-fortified salt (DFS) containing 47 mg potassium iodate/kg and 3.3 mg microencapsulated ferrous fumarate/g (1.1 mg elemental Fe/g)
Study: 22912456
Drug: Dietary choline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary choline supplementation at 2,960 mg/kg
Study: 22912456
Drug: Dietary choline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary choline supplementation at 370 mg/kg
Study: 19330795
Drug: Venlafaxine SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine SR (75-150 mg/die)
Study: 19330795
Drug: Fluoxetine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-40 mg/die)